Whole blood GBP5 protein levels in patients with and without active tuberculosis

BMC Infectious Diseases

卷:22

Ningshao Xia¹  Zhouyue Zhong¹  Zhitan Ge¹  Yongliang Liu¹  Shuping Chen¹  Tingdong Li¹  Shengxiang Ge¹  Yingbin Wang¹  Chenxi Deng¹  Shiyin Zhang¹  Wei Liu¹  Xuejie Zhang¹  Xiaofei Li²  Chao Zheng³  Xiangyang Yao³ 

[1] State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Disease, Collaborative Innovation Centers of Biological Products, School of Public Health, Xiamen University;

[2] Third People’s Hospital of Kunming City;

[3] Xinglin Branch of the First Affiliated Hospital of Xiamen University;

关键词: Guanylate binding protein 5;    Whole blood;    Protein level;    Active tuberculosis;    Interferon-gamma release assay;   

DOI  :  10.1186/s12879-022-07214-8

来源: DOAJ

【 摘 要 】

Abstract Background The host blood transcriptional levels of several genes, such as guanylate binding protein 5 (GBP5), have been reported as potential biomarkers for active tuberculosis (aTB) diagnosis. The aim of this study was to investigate whole blood GBP5 protein levels in aTB and non-tuberculosis patients. Methods An in-house immunoassay for testing GBP5 protein levels in whole blood was developed, and suspected aTB patients were recruited. Whole blood samples were collected and tested at enrolment using interferon-gamma release assay (IGRA) and the GBP5 assay. Results A total of 470 participants were enrolled, and 232 and 238 patients were finally diagnosed with aTB and non-TB, respectively. The GBP5 protein levels of aTB patients were significantly higher than those of non-tuberculosis patients (p < 0.001), and the area under the ROC curve of the GBP5 assay for aTB diagnosis was 0.76. The reactivity of the GBP5 assay between pulmonary and extrapulmonary tuberculosis patients was comparable (p = 0.661). With the optimal cut-off value, the sensitivity and specificity of the GBP5 assay for diagnosing aTB were 78.02 and 66.81%, respectively, while those of IGRA were 77.59 and 76.47%. The combination of the GBP5 assay and IGRA results in 88.52% accuracy for diagnosing aTB in 63.83% of suspected patients with a positive predictive value of 89.57% and a negative predictive value of 87.59%. Conclusions Whole blood GBP5 protein is a valuable biomarker for diagnosing of aTB. This study provides an important idea for realizing the clinical application of whole blood transcriptomics findings by immunological methods.

【 授权许可】

Unknown